Evolent Health, Inc. (NYSE: EVH) has reconfirmed its second-quarter 2025 adjusted EBITDA guidance, expecting it to be in the range of $33 million to $40 million. Moreover, the company has also reiterated its full-year adjusted EBITDA guidance, projecting it to be between $135 million and $165 million.
The company's chief financial officer, John Johnson, expressed satisfaction with the oncology cost trend, which has remained below expectations for the majority of the second quarter. With confidence in meeting or surpassing the set expectations for the quarter and the full year, Johnson stated that if the trends persist through June, they anticipate being in the top half of the range for Q2 adjusted EBITDA.
Furthermore, Evolent Health has signed a commitment letter with Ares Management Credit Funds, securing the option to borrow additional non-dilutive capital to address its 2025 convertible notes. This move is aimed at leaving incremental working capital on its balance sheet to support Evolent's accelerating organic growth pipeline.
Seth Blackley, the company's CEO, highlighted a recent acceleration in business development activities, leading to a significant increase in the forecast for new revenue bookings as they move into 2026. This forecasted growth has prompted the company to secure the availability of incremental, non-dilutive capital to address any associated working capital needs.
Evolent Health, Inc., which specializes in better health outcomes for individuals with complex conditions, serves a national base of leading payers and providers. The company has been consistently recognized as a top place to work in healthcare nationally.
Following these announcements, the company's shares moved 10.52%, and are now trading at a price of $9.56. If you want to know more, read the company's complete 8-K report here.
